Indivior Acquires Opiant Pharmaceuticals for $145M
Ticker: INDV · Form: 8-K · Filed: Apr 24, 2025 · CIK: 1625297
Sentiment: bullish
Topics: acquisition, healthcare, pharmaceuticals, debt
TL;DR
Indivior just bought Opiant for $145M to boost its addiction treatment game. Big win for overdose reversal.
AI Summary
Indivior PLC announced on April 24, 2025, that it has completed the acquisition of Opiant Pharmaceuticals, Inc. for an aggregate purchase price of approximately $145 million. This strategic move aims to expand Indivior's portfolio in addiction treatment, particularly with Opiant's lead product, LARO, a nasal naloxone spray for opioid overdose.
Why It Matters
This acquisition strengthens Indivior's position in the addiction treatment market by adding Opiant's promising opioid overdose reversal product, potentially leading to new revenue streams and improved patient outcomes.
Risk Assessment
Risk Level: medium — The acquisition involves integration risks and market acceptance of Opiant's products, which could impact the expected financial returns.
Key Numbers
- $145M — Acquisition Price (Total cost for Indivior to acquire Opiant Pharmaceuticals.)
Key Players & Entities
- Indivior PLC (company) — Acquiring company
- Opiant Pharmaceuticals, Inc. (company) — Acquired company
- $145 million (dollar_amount) — Aggregate purchase price
- April 24, 2025 (date) — Date of announcement/completion
- LARO (product) — Opiant's lead product for opioid overdose
FAQ
What is the primary strategic rationale behind Indivior's acquisition of Opiant Pharmaceuticals?
Indivior aims to expand its portfolio in addiction treatment, specifically by incorporating Opiant's lead product, LARO, a nasal naloxone spray for opioid overdose.
What was the total financial consideration for the acquisition of Opiant Pharmaceuticals?
The aggregate purchase price for Opiant Pharmaceuticals was approximately $145 million.
When was the acquisition of Opiant Pharmaceuticals by Indivior PLC announced or completed?
The acquisition was announced/completed on April 24, 2025.
What is the key product Indivior is gaining from Opiant Pharmaceuticals?
Indivior is gaining Opiant's lead product, LARO, which is a nasal naloxone spray designed to treat opioid overdose.
What is Indivior PLC's primary business focus?
Indivior PLC is focused on the pharmaceutical preparations industry, specifically in addiction treatment.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 24, 2025 regarding INDIVIOR PLC (INDV).